Top 10 Global Pharmaceutical Productivity 2021

Recently, Fierce Pharma ranked the world's most productive biopharmaceutical companies, screening out the top ten biopharmaceutical companies, let's take a
look.

1 BioNTech

2021 Number of Employees: 3082

2021 revenue: €18.

Per capita income in 2021: $7.

Per capita income in 2020: about $246,000

Instead of flying alone with its mRNA-based COVID-19 vaccine like rival Moderna, BioNTech has partnered with companies like Regeneron on vaccine research and has set its sights on mRNA projects and other companies
like cell therapy.

Currently, BioNTech is adding staff, expanding manufacturing, and developing mRNA production programs
in places like Africa.

At the end of 2021, the company had 3,082 employees worldwide, approximately 1,000 more than in 2020, when BioNTech had 1,941 employees
.

The Marlborough plant, one of the world's largest mRNA vaccine plants, will add around 250 jobs by 2022 and currently employs around 500 people
.

The company also reportedly plans to develop other approved mRNA vaccines there, such as the flu and shingles vaccines
developed in collaboration with Pfizer.

2 Moderna

Number of employees in 2021: 2700

2021 revenue: $18.

Per capita income in 2021: $6.

Per capita income in 2020: about $618,000

Moderna's goal is to build its own mRNA empire, and it is increasing its numbers and expanding its commercial boundaries to achieve this
.

Unlike BioNTech, Moderna did not take the partnership, but instead laid out its own path to the market
.

In 2019, Moderna employed approximately 820 people
.

Comparing Moderna's headcount to its $18.

In February, Moderna outlined plans
to open four new subsidiaries in Hong Kong, Malaysia, Singapore and Taiwan.

Moderna is then also developing its presence in Europe, with the next one in Belgium, Denmark, the Netherlands, Norway, Poland and Sweden
.

3 Gilead Sciences

2021 Number of Employees: 14,000

2021 revenue: $27.
31 billion

Per capita income in 2021: $1.
95 million

Per capita income in 2020: $1.
82 million

In 2021, Gilead's development is mainly focused on the new crown drug Veklury
.
The drug reached $5.
6 billion in sales last year, up 98 percent
from 2020.
Thanks to this, Gilead's total revenue grew 11% last year to $27.
3 billion.

At the end of 2021, the company employed 14,000 people, which brought Gilead's per capita income to $1.
95 million last year, a 7%
increase from $1.
82 million in 2020.

The company is working to develop oncology products, including breast cancer drugs Trodelvy and cell therapies Yescarta and Tecartus
.
Gilead also has 20 oncology drugs under development and 30 clinical trials underway
.
Oncology products will be Gilead's R&D focus, and by 2030, 1/3 of its revenue will come from this, and in 2021, the revenue of oncology products will account for less than 7%
of its total sales.

In April 2022, the company laid off 114 people as it prepares to move plants
.
At the same time, the company acquired 27 acres of undeveloped land near its existing facility in Oceanside, California, to boost manufacturing
in the area.

Gilead will also work to increase the diversity of its workforce and pledge to hire or promote 200 black Americans without four-year degrees and increase the percentage of Hispanics in its U.
S.
workforce to 15 percent while also increasing the percentage of women in leadership to 39 percent
.

4 Regeneron

2021 Number of Employees: 10368

2021 revenue: $16.
07 billion

Per capita income in 2021: $155.
<> million

Per capita income in 2020: $93.
<> million

By 2021, Regenerative already has one of
the most productive workforces in the biopharmaceutical sector.
This is thanks to the development
of Eylea, a blockbuster drug for the treatment of macular degeneration, and Dupixent, which treats eczema and asthma.

When the COVID-19 pandemic came, Regenerative responded quickly with the launch of the COVID-19 antibody cocktail therapy "REGEN-COV"
.
The therapy was authorized for emergency use by the FDA in November 2020, and in 2021, REGEN-COV sales were $7,573.
9 million
.
This brings total revenue of Renewal Element to $16.
1 billion in 2021, up from just $8.
5 billion
in 2020.

Meanwhile, Eylea's global sales grew from $7.
9 billion in 2020 to $9.
4 billion in 2021, while Dupixent's sales grew from $4 billion in 2020 to $6.
2 billion
.

While the company has successfully commercialized its therapies in the U.
S.
, it has left those responsibilities outside the U.
S.
to large corporations
.
Outside the U.
S.
, Regeneration has partnered with Bayer to develop Eylea, Roche to develop REGEN-COV, and Sanofi to have a global partnership
on Dupixent.

The company added 1,245 jobs in 2021, from 9,123 employees at the end of 2020 to 10,368 at
the end of 2021.
Because of the company's good results this year, the company has spent a lot of money on top talent, adding about 200 positions with Ph.
D.
or medical doctorates, bringing Regeneron's total to more than 1,200 people, Regeneron said
.

Due to the failure of REGEN-COV to the Omicron variant, the sale of REGEN-COV has come to a sudden halt
.
In 2022, per capita income from regenerative elements is expected to return to pre-pandemic levels
.

5 Bristol Myers Squibb

2021 Number of Employees: 32200

2021 revenue: $463.
9 billion

Per capita income in 2021: $144.
<> million

Per capita income in 2020: $141.
<> million

According to 2016 data, BMS ranked seventh at the time, and later it acquired Celgene
, which ranked second that year, through $74 billion.
By consolidating Celgene, BMS expects to save $3 billion
annually by 2022.

Some of the cost savings from BMS also come from layoffs
.
In 2018, BMS and Celgene had a total of 32,150 employees, and by the end of 2019, the combined BMS was reduced to 30,000 employees
.
In 2021, BMS will employ 32,200 people, an increase of 6.
4%.

Meanwhile, the company has revenue of $46.
39 billion in 2021, up 9.
1 percent
year-over-year, thanks to contributions from three best-selling drugs of Revlimid, Eliquis, and Opdivo.

While revenue increased, BMS scaled back some of its production scale
.
Last year, the company sold its capsule and tablet manufacturing facility in Switzerland to WuXi AppTec's STA company
.

Meanwhile, with the FDA approving CAR-T therapies Breyanzi and Abecma in 2021, BMS began expanding its cell therapy production capacity
.
Last November, BMS officially opened a new cell therapy facility in Devons, Massachusetts, enrolling 150 new employees and plans to add hundreds of jobs
.
The company is also building a new facility in Leiden, Netherlands, which is expected to open by the end of 2024 and offers "hundreds" of new positions
.

6 Biogen

2021 Number of Employees: 9610

2021 revenue: $109.
8 billion

Per capita income in 2021: $114.
<> million

Per capita income in 2020: $148.
<> million

Since Biogen hired more employees last year, its revenue has declined, which is not the winning secret
to improving its productivity rankings.
Still, as a relatively small pharmaceutical company, it ranks among the top 10 most productive biopharmaceutical companies
.

In 2021, Biogen's productivity fell by 23% and its per capita income was $1.
14 million.

In the 2016 list, Biogen had a total of 7,400 employees, ranking third
with a per capita income of $1.
55 million.
At the end of 2021, Biogen had 9,610 employees, up 6%
from 2020.

Meanwhile, Biogen's revenue in 2021 was $10.
98 billion, down 18%
year-on-year.
Tecfidera sales fell nearly half to $1.
95 billion as generic drugs in the U.
S.
hit
Biogen's once-best-selling drug.
Spinraza, a new drug for spinal muscular atrophy, was previously Biogen's second-best-selling product, and Spinraza's sales also slipped
last year due to drug competition from Novartis and Roche.

Biogen also plans to lay off employees, saving $1 billion a year in costs
.
The exact number of layoffs is unclear, but Biogen will reportedly lay off more than 1,000 jobs
.

7 AbbVie

2021 Number of Employees: 50000

2021 revenue: $56.
2 billion

Per capita income in 2021: $112.
<> million

Per capita income in 2020: $97.
<> million

While many of the pharmaceutical companies in this report employ fewer employees by the standards of large pharmaceutical companies, AbbVie's total workforce is only behind U.
S.
vaccine manufacturing giant Pfizer
in this ranking.
By the end of January, AbbVie had employed about 50,000 people, up slightly from 47,000 in January 2021
.

As a global pharmaceutical giant, AbbVie generated $56.
2 billion in revenue last year, up 22 percent from 2020, with $20.
7 billion coming from its immunology blockbuster Humira, which accounts for 37 percent
of AbbVie's total sales.
Last year, many of AbbVie's peers achieved revenue growth with COVID-19 treatment products, but AbbVie's growth came from its core products, and the company ranked fourth
among large drugmakers in sales last year.

But with Humira set to face tremendous generic pressures in 2023, it remains to be seen
how AbbVie's financial position will change.
Amgen plans to launch the launch of Humira biosimilars in January 2023, and several other companies plan to launch
generic drugs in batches next year.

Among AbbVie's other product portfolios, revenue from the anti-cancer drug Imbruvica increased by 2% to $5.
4 billion, and revenue from new immunology products Skyrizi and Rinvoq increased considerably, and AbbVie expects total sales of these two immune drugs to reach $15 billion
by 2025.

AbbVie said the median compensation last year was $
149,662.
Since CEO Richard Gonzalez received more than $23.
9 million in compensation, the company's CEO to employee compensation ratio has been 160:1
.

8 Amgen

2021 Number of Employees: 24200

2021 revenue: $259.
8 billion

Per capita income in 2021: $107.
<> million

Per capita income in 2020: $105.
<> million

Although Amgen has failed to meet its 2021 revenue target, the company has recently been busy with cancer research and development, layoffs, manufacturing investments and more
.
In 2021, Amgen will achieve global sales of $25.
98 billion
.
The company has a per capita income of $1.
07 million in 2021, surpassing most companies
in the industry.

Although Amgen maximized the acquisition of Otezla and developed Lumakras, an anti-cancer product, the company only added about 100 employees
last year.
Amgen's U.
S.
sales team, meanwhile, was hit hard in February as the company laid off about 500 people
.

But for Amgen, last year's goal was not just to cut costs
.
The company invested $365 million in smart facilities in New Albany, Ohio, in June 2021, and the 270,000-square-foot facility will open in 2024 and will employ 400 people
by then.
It will be Amgen's "state-of-the-art digital facility.
"
Two months later, Amgen pledged $550 million to build a production site
in North Carolina.

Amgen plans to launch a generic drug
of Humira in January next year.
In addition, last year Amgen received FDA approval to make Lumakras the first drug
to treat non-small cell lung cancer with a KRAS G12C mutation.
The approval was a huge victory because the mutation had been considered incurable
.

9 Pfizer

2021 Number of Employees: 79000

2021 revenue: $812.
9 billion

Per capita income in 2021: $103.
<> million

In 2020, revenue per employee: $540,000

During the pandemic, Pfizer has achieved impressive results, reducing the number of employees by nearly 10,000 and increasing revenue by nearly 100%.

Benefiting from the sale of COVID-19 vaccines, Pfizer's revenue increased from $40.
9 billion in 2019 to $81.
3 billion
in 2021.

Pfizer, meanwhile, reduced its workforce from 88,300 to 79,000, largely due to the company's divestiture of its generic division Upjohn
in the fourth quarter of 2020.
According to documents filed by the U.
S.
Securities and Exchange Commission (SEC), in September 2019, Upjohn had 2,377 employees
.

Although Pfizer's revenue has almost doubled, it still controls the number of employees, with only about 500 more employees at the end of 2021 than at the beginning of the year
.

Big pharma companies like Pfizer, which are focused on growth, have been experts at preventing bloat
.
In 2009, the company went into a $68 billion merger with Wyeth, and the combined companies had 81,800 employees and 47,426 employees at the end of 2008
.
A year later, Pfizer cut the total number of employees in both companies to 116,500, and by the end of 2013, the company had cut the number of employees to 77,700
.

In addition to the layoffs, the divestiture of the generic division has also helped Pfizer maintain a relatively stable number of employees, as the company will acquire more promising companies through mergers and acquisitions
.
In 2015, when Pfizer acquired Hospira, the world's largest supplier of injectable drugs, the company's workforce surged to 97,900
.

Pfizer remains the largest company on the list of the top 10 biopharma companies with the highest production efficiency in 2021 so far; This is followed by AbbVie, with 50,000 employees; The third is Eli Lilly, which employs 35,000 people
.

Last year, while Pfizer's revenue increased by nearly $40 billion, its cost of sales soared from $8.
7 billion to $30.
8 billion, and research and development expenses rose from $9.
4 billion to $13.
8 billion.

But the company said in the report that those increases had nothing to do
with the increased manpower.
Due to the impact of the COVID-19 vaccine Comirnaty, 50% gross profit sharing fees and patent royalties with BioNTech have led to a rapid increase
in the cost of sales.

In 2022, Pfizer's per capita income is expected to increase
significantly.
The company's revenue in the first half of 2022 was $54.
3 billion, with Comirnaty and oral anti-coronavirus drug Paxlovid combined to exceed $31 billion
.

10 Eli Lilly

2021 Number of Employees: 35000

2021 revenue: $283.
2 billion

Per capita income in 2021: $81.
<> million

Revenue per employee in 2020: $701,000

Over the past few years, Eli Lilly has been working to update its portfolio of marketed drugs to replace sales of older drugs with new marketed drugs, and its efforts are also paying off
.

By the end of 2021, Eli Lilly had 35,000 employees
.
In addition, Lilly had global sales of $28.
3 billion last year, ranking 12th
among all biopharmaceutical companies.

The company has undergone a lot of changes
over the past few years.
In early 2017, shortly after CEO David Ricks took the helm, the company launched a massive cost-cutting campaign aimed at saving $1.
2 billion a year.

As a result, Lilly laid off about 3,500 people, many of whom received higher retirement benefits
.

At the end of 2016, Eli Lilly employed nearly 42,000 people
.
The company's newest total current is about 35,000 and has actually laid off about 7,000 over
the years.
At the same time, Lilly's revenue increased during this time, significantly increasing per capita income
.
In 2016, the company's per capita income was about $505,000
.

Over the years, the company has been ramping up new drug research and
development.
Back in 2016, Lilly reportedly relied on vintage drugs
for 86 percent of its sales.

Today, the situation is completely different
.
In the second quarter of this year, Eli Lilly reported that its newly launched products accounted for 67% of its total sales, excluding COVID-19 antibody revenue
.
Eli Lilly's new products include Trulicity, a type 2 diabetes drug, Verzenio, a breast cancer drug, Taltz, an immunology blockbuster, Emgality, a migraine-preventing drug, and more
.

Last year, the company's COVID-19 neutralizing antibodies also played a major role, reaching $2.
24 billion, which is about 8%
of total sales.

Resources: